These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 36209563

  • 1. Design, synthesis and pharmacological evaluation of 2-arylurea-1,3,5-triazine derivative (XIN-9): A novel potent dual PI3K/mTOR inhibitor for cancer therapy.
    Sun X, Zhang B, Luo L, Yang Y, He B, Zhang Q, Wang L, Xu S, Zheng P, Zhu W.
    Bioorg Chem; 2022 Dec; 129():106157. PubMed ID: 36209563
    [Abstract] [Full Text] [Related]

  • 2. Design, synthesis and antitumor activity of novel thiophene- triazine derivatives bearing arylurea unit as potent PI3K/mTOR inhibitorss.
    Xu S, Luo L, Sun X, Yang Y, Guo Q, Jiang Z, Wu Y.
    Bioorg Med Chem; 2023 Jan 15; 78():117133. PubMed ID: 36599263
    [Abstract] [Full Text] [Related]

  • 3. A Novel Dual PI3K/mTOR Inhibitor, XIN-10, for the Treatment of Cancer.
    Luo L, Sun X, Yang Y, Xia L, Wang S, Fu Y, Zhu Y, Xu S, Zhu W.
    Int J Mol Sci; 2023 Oct 01; 24(19):. PubMed ID: 37834269
    [Abstract] [Full Text] [Related]

  • 4. Discovery of novel potent PI3K/mTOR dual-target inhibitors based on scaffold hopping: Design, synthesis, and antiproliferative activity.
    Yang Y, Sun X, Luo L, Peng R, Yang R, Cheng Z, Lv Y, Li H, Tang Q, Zhu W, Qiao D, Xu S.
    Arch Pharm (Weinheim); 2023 Dec 01; 356(12):e2300403. PubMed ID: 37840368
    [Abstract] [Full Text] [Related]

  • 5. Discovery of novel 1,3,5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K/mTOR.
    Hu J, Zhang Y, Tang N, Lu Y, Guo P, Huang Z.
    Bioorg Med Chem; 2021 Feb 15; 32():115997. PubMed ID: 33440319
    [Abstract] [Full Text] [Related]

  • 6. Design, synthesis and biological evaluation of substituted 2-(thiophen-2-yl)-1,3,5-triazine derivatives as potential dual PI3Kα/mTOR inhibitors.
    Zhang B, Zhang Q, Xiao Z, Sun X, Yang Z, Gu Q, Liu Z, Xie T, Jin Q, Zheng P, Xu S, Zhu W.
    Bioorg Chem; 2020 Jan 15; 95():103525. PubMed ID: 31887474
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Design, synthesis, and biological evaluation of novel benzimidazole derivatives as anti-cervical cancer agents through PI3K/Akt/mTOR pathway and tubulin inhibition.
    Li SS, Chen JJ, Zhang MM, Wang WX, Zhang WY, Ma C.
    Eur J Med Chem; 2024 May 05; 271():116425. PubMed ID: 38636129
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Discovery of N-(2-chloro-5-(3-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide (FD274) as a highly potent PI3K/mTOR dual inhibitor for the treatment of acute myeloid leukemia.
    Yang C, Chen Y, Wu T, Gao Y, Liu X, Yang Y, Ling Y, Jia Y, Deng M, Wang J, Zhou Y.
    Eur J Med Chem; 2023 Oct 05; 258():115543. PubMed ID: 37329712
    [Abstract] [Full Text] [Related]

  • 14. PI3Kδ and mTOR dual inhibitors: Design, synthesis and anticancer evaluation of 3-substituted aminomethylquinoline analogues.
    Yevale D, Teraiya N, Lalwani T, Dalasaniya M, Kapadiya K, Ameta RK, Sangani CB, Duan YT.
    Bioorg Chem; 2024 Jun 05; 147():107323. PubMed ID: 38583254
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
    Mohan S, Vander Broek R, Shah S, Eytan DF, Pierce ML, Carlson SG, Coupar JF, Zhang J, Cheng H, Chen Z, Van Waes C.
    Clin Cancer Res; 2015 Sep 01; 21(17):3946-56. PubMed ID: 25977343
    [Abstract] [Full Text] [Related]

  • 17. New quinoline/chalcone hybrids as anti-cancer agents: Design, synthesis, and evaluations of cytotoxicity and PI3K inhibitory activity.
    Abbas SH, Abd El-Hafeez AA, Shoman ME, Montano MM, Hassan HA.
    Bioorg Chem; 2019 Feb 01; 82():360-377. PubMed ID: 30428415
    [Abstract] [Full Text] [Related]

  • 18. Synthesis, Molecular Docking, In Vitro and In Vivo Studies of Novel Dimorpholinoquinazoline-Based Potential Inhibitors of PI3K/Akt/mTOR Pathway.
    Zapevalova MV, Shchegravina ES, Fonareva IP, Salnikova DI, Sorokin DV, Scherbakov AM, Maleev AA, Ignatov SK, Grishin ID, Kuimov AN, Konovalova MV, Svirshchevskaya EV, Fedorov AY.
    Int J Mol Sci; 2022 Sep 17; 23(18):. PubMed ID: 36142768
    [Abstract] [Full Text] [Related]

  • 19. Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 Positive Feedback Loop Induces Cell Cycle Arrest by Dual PI3K/mTOR Inhibitor PQR309 in Endometrial Cancer Cell Lines.
    Hsin IL, Shen HP, Chang HY, Ko JL, Wang PH.
    Cells; 2021 Oct 27; 10(11):. PubMed ID: 34831139
    [Abstract] [Full Text] [Related]

  • 20. 1H-Indazoles derivatives targeting PI3K/AKT/mTOR pathway: Synthesis, anti-tumor effect and molecular mechanism.
    Wang S, Shi JT, Wang XR, Mu HX, Wang XT, Xu KY, Wang QS, Chen SW.
    Bioorg Chem; 2023 Apr 27; 133():106412. PubMed ID: 36773456
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.